NATCO Pharma Ltd.

1 clinical trials · Sponsor

Record	Firm	Date
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy (NCT05283226)	NATCO Pharma Ltd.	2022-09-30

Every clearance here is in the API, with alerts when new ones post.